Skip to main content
PBLS logo

PBLS · Parabilis Medicines, Inc. · Holdings

Track PBLS — free
$28.88 +0.63 (+2.23%)
Market Cap
$3.54B
Shares
125.26M
Volume · Nov 18 193.85K Avg daily vol (3M) 944.98K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 128
Total Value: $3,555,407,047
Total Shares: 110,108,682
Showing 1–100 of 130 holdings by value · page 1 of 2

Institutional Ownership Trend

2 quarters

Holder Concentration

Share of 13F common-share value, across 128 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
26.5%
Jun 2026 → Sep 2026 · range 26.5% – 29.2%
−2.7 pts
Top 5
51.4%
Jun 2026 → Sep 2026 · range 51.4% – 56.4%
−5.0 pts
Top 10
69.3%
Jun 2026 → Sep 2026 · range 69.3% – 75.4%
−6.1 pts
HHI
980
Jun 2026 → Sep 2026 · range 980 – 1,165
Broadly held−185

Who Holds PBLS

Last 2 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 127 filers, like-for-like change +9.8%; actively managed books +3.5%; index-like books +478.1%.

Holder type Share Filers Change
Registered adviser 49.0% 58 +6.0%
Exempt adviser 15.2% 5 -0.2%
Adviser 3.8% 6 +7.6%
Bank 2.3% 13 +137.0%
Insurer 0.0% 1 new
Broker-dealer 0.0% 1 new
Benefit plan 0.0% 2 new
Non-US 0.7% 5 +49.3%
Holding company 13.0% 6 +39.0%
Unknown 15.9% 30 +3.9%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-06-30 13F and 1 holder with no observed 2026-09-30 13F.

Conviction and Crowding

127 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
13
10.2% of filers hold it in their top 10
Jun 30, 2026: 11
Holders above 5%
9
median weight 0.001%
Jun 30, 2026: 7
Crowding
—
the issuer has more than one class of common stock, so its count is the total across classes
Private-fund advisers
—
of shares outstanding
Institutional ownership
—
the issuer has more than one class of common stock, so its count is the total across classes
Top 10 holders
69.3%
of 13F shares, Herfindahl 0.098
Active holders
+3.5%
like-for-like share change of active filers
5% stakes on record
3
1 13D, 2 13G (1 institutional, 0 passive, 1 exempt)
How long holders have held it value-weighted 1.9 quarters
Under 1 year 100.0% 1 to 3 years 0.000% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $50,550,506 (6 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$34.90
estimated per share
Quarter-end price
$32.29
implied by 13F values
Estimated gain or loss
-7.5%
price against the estimated cost
Estimated at a loss
100.0%
of costed 13F value

Estimated cost covers 4.79% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies PBLS's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 JBIO Jade Biosciences, Inc. 9
2 SPTX Seaport Therapeutics, Inc. 6
3 MAZE Maze Therapeutics, Inc. 8
4 BRVE Braveheart Bio, Inc. 7
5 ETRA Electra Therapeutics, Inc. 7
6 PRLD Prelude Therapeutics Inc 4
7 IRON Disc Medicine, Inc. 9
8 FRNM Freenome, Inc. 7
9 SEPN Septerna, Inc. 7
10 KLRA Kailera Therapeutics, Inc. 5

Shareholder Targets

13F filers that own its peers but not PBLS, quarter ended Sep 30, 2026

Found through its holder-overlap peers: JBIO, SPTX, MAZE, BRVE, ETRA, PRLD, IRON, FRNM, SEPN, KLRA, COAG, TYRA, GPCR, RLAY, ENTX, TCGX, BBOT, TNGX, VTVT, ERAS. 497 filers in all.

# Filer In peers
1 RTW INVESTMENTS, LP Registered adviser, Diversified active $887,670,828 6 held
2 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $691,823,853 6 held
3 PERCEPTIVE ADVISORS LLC Registered adviser, Diversified active $540,116,993 7 held
4 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $516,553,020 7 held
5 Deep Track Capital, LP Adviser, Diversified active $501,160,256 6 held
6 ORBIMED ADVISORS LLC Registered adviser, Diversified active $499,797,418 6 held
7 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $441,782,122 9 held
8 FCPM III SERVICES B.V. Unknown, Concentrated $440,885,684 1 held
9 TCG Crossover Management, LLC Unknown, Diversified active $436,799,849 5 held
10 SB INVESTMENT ADVISERS (UK) LTD Registered adviser, Concentrated $395,384,582 1 held

Fund Ownership of PBLS by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 1.96% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.03% 35,962
Index ETFs 1.94% 2,424,217
Active ETFs 0.00% 0
Active funds 1.73% 2,168,765
Unclassified 0.00% 0
All registered funds 3.70% 4,628,944
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
58
Increased
26
Decreased
10
Sold Out
10
Unchanged
32

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +49
Institutional value: +31.3%
Shares held: +11.3%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 130
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 130 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1657677 CUSIP 698955101 13F (30d) 124 filings 124 filers Visit website Investor relations